ASRT · Assertio Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.93M | - | $49.46M | $29.22M | $26.49M | - | $29.20M | $31.13M | $32.45M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $454.0K | - | $379.0K | $387.0K | $438.0K | - | $1.00M | $798.0K | $733.0K | - |
| SG&A | $19.43M | - | $16.93M | $16.96M | $21.98M | - | $16.73M | $18.39M | $18.52M | - |
| Total Operating Expenses | $28.40M | - | $37.98M | $37.26M | $39.72M | - | $32.25M | $34.74M | $36.78M | - |
| D&A | $5.84M | - | $100.0K | $100.0K | $9.27M | - | $100.0K | $100.0K | $5.70M | - |
| Operating Income | ($18.47M) | - | $11.48M | ($8.04M) | ($13.23M) | - | ($3.05M) | ($3.62M) | ($4.34M) | - |
| Interest Expense | $775.0K | - | $770.0K | $758.0K | - | - | $0 | $0 | $0 | - |
| Income Tax | $45.0K | - | ($47.0K) | $56.0K | $245.0K | - | $44.0K | $149.0K | $132.0K | - |
| Net Income | ($18.86M) | - | $11.45M | ($16.35M) | ($13.54M) | - | ($2.92M) | ($3.67M) | ($4.51M) | - |
| EPS - Basic | ($2.93) | - | $1.80 | ($2.55) | ($2.10) | - | ($0.45) | ($0.60) | ($0.75) | - |
| EPS - Diluted | ($2.93) | - | $1.65 | ($2.55) | ($2.10) | - | ($0.45) | ($0.60) | ($0.75) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $33.71M | $10.23M | $38.50M | $47.09M | $35.00M | $50.59M | $37.98M | $44.73M | $80.74M | $73.44M |
| Accounts Receivable | $61.53M | $120.11M | $141.31M | $61.09M | $66.29M | $54.12M | $44.94M | $39.91M | $42.61M | $47.66M |
| Inventory | $23.01M | $24.12M | $24.76M | $32.88M | $39.40M | $38.31M | $39.79M | $39.08M | $38.60M | $37.69M |
| Accounts Payable | $5.91M | $9.01M | $14.66M | $10.85M | $8.90M | $14.74M | $13.15M | $15.27M | $15.65M | $13.44M |
| Current Assets | $166.85M | $216.65M | $263.57M | $210.21M | $213.55M | $202.55M | $181.16M | $177.85M | $172.47M | $171.06M |
| Total Assets | $211.30M | $266.97M | $319.77M | $273.78M | $286.43M | $284.73M | $276.00M | $279.44M | $281.96M | $286.42M |
| Current Liabilities | $91.57M | $127.51M | $166.78M | $132.53M | $128.83M | $114.69M | $90.10M | $92.18M | $92.44M | $93.44M |
| Long-term Debt | $39.25M | $39.12M | $39.17M | $39.05M | $38.93M | $38.81M | $38.84M | $38.73M | $38.62M | $38.51M |
| Total Liabilities | $135.67M | $173.02M | $213.97M | $180.48M | $177.90M | $163.65M | $145.48M | $147.29M | $147.47M | $148.42M |
| Stockholders' Equity | $75.63M | $93.95M | $105.80M | $93.30M | $108.53M | $121.08M | $130.52M | $132.15M | $134.49M | $138.00M |
| Retained Earnings | ($722.36M) | ($703.50M) | ($691.57M) | ($703.02M) | ($686.66M) | ($673.12M) | ($662.65M) | ($659.73M) | ($656.05M) | ($651.54M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $8.56M | - | - | - | ($12.54M) | - | - | - | $7.51M | - |
| Investing Cash Flow | $15.11M | - | - | - | ($2.94M) | - | - | - | $0 | - |
| Financing Cash Flow | ($189.0K) | - | - | - | ($111.0K) | - | - | - | ($206.0K) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -185.9% | - | 23.2% | -27.5% | -50.0% | - | -10.4% | -11.6% | -13.4% | - |
| EBITDA margin | -127.2% | - | 23.4% | -27.2% | -15.0% | - | -10.1% | -11.3% | 4.2% | - |
| Net margin | -189.8% | - | 23.1% | -56.0% | -51.1% | - | -10.0% | -11.8% | -13.9% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 4.6% | - | 0.8% | 1.3% | 1.7% | - | 3.4% | 2.6% | 2.3% | - |
| SG&A / Revenue | 195.7% | - | 34.2% | 58.0% | 83.0% | - | 57.3% | 59.1% | 57.1% | - |
| Effective tax rate | - | - | -0.4% | - | - | - | - | - | - | - |
| Return on assets | -8.9% | - | 3.6% | -6.0% | -4.7% | - | -1.1% | -1.3% | -1.6% | - |
| Return on equity | -24.9% | - | 10.8% | -17.5% | -12.5% | - | -2.2% | -2.8% | -3.4% | - |
| Return on invested capital | -12.7% | - | 7.9% | -4.8% | -7.1% | - | -1.4% | -1.7% | -2.0% | - |
| Liquidity | ||||||||||
| Current ratio | 1.82 | 1.70 | 1.58 | 1.59 | 1.66 | 1.77 | 2.01 | 1.93 | 1.87 | 1.83 |
| Quick ratio | 1.57 | 1.51 | 1.43 | 1.34 | 1.35 | 1.43 | 1.57 | 1.51 | 1.45 | 1.43 |
| Cash ratio | 0.37 | 0.08 | 0.23 | 0.36 | 0.27 | 0.44 | 0.42 | 0.49 | 0.87 | 0.79 |
| Leverage | ||||||||||
| Debt / Equity | 0.52 | 0.42 | 0.37 | 0.42 | 0.36 | 0.32 | 0.30 | 0.29 | 0.29 | 0.28 |
| Debt / Assets | 0.19 | 0.15 | 0.12 | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | 0.13 |
| Debt / EBITDA | - | - | 3.38 | - | - | - | - | - | 28.42 | - |
| Interest coverage | -23.8x | - | 14.9x | -10.6x | - | - | - | - | - | - |
| Equity multiplier | 2.79 | 2.84 | 3.02 | 2.93 | 2.64 | 2.35 | 2.11 | 2.11 | 2.10 | 2.08 |
| Liabilities / Assets | 0.64 | 0.65 | 0.67 | 0.66 | 0.62 | 0.57 | 0.53 | 0.53 | 0.52 | 0.52 |
| Efficiency | ||||||||||
| Asset turnover | 0.05 | - | 0.15 | 0.11 | 0.09 | - | 0.11 | 0.11 | 0.12 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 2261d | - | 1043d | 763d | 913d | - | 562d | 468d | 479d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | 8.0x | - | - | - | - | - | - | - |
| P / B | 1.6x | - | 13.3x | 9.9x | 8.9x | - | 12.9x | 13.4x | 10.2x | - |
| P / S | 12.3x | - | 28.4x | 31.5x | 36.3x | - | 57.8x | 56.9x | 42.2x | - |
| EV / EBITDA | - | - | 121.5x | - | - | - | - | - | 975.4x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -62.5% | - | 69.4% | -6.1% | -18.4% | - | -18.0% | -24.1% | -23.6% | - |
| Revenue CAGR (3y) | -38.4% | - | 13.1% | -6.0% | -10.2% | - | 4.7% | 7.0% | 15.8% | - |
| Revenue CAGR (5y) | -13.8% | - | -2.2% | -12.6% | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -39.6% | - | - | -122.1% | -205.1% | - | 98.7% | - | - | - |
| Net income growth (YoY) | -39.3% | - | - | -345.1% | -200.2% | - | 99.0% | - | -29.4% | - |
| EPS growth (YoY) | -39.5% | - | - | -325.0% | -180.0% | - | 86.8% | - | -971.4% | - |
| EPS CAGR (3y) | - | - | 174.2% | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -30.3% | -22.4% | -18.9% | -29.4% | -19.3% | -12.3% | -32.3% | -48.0% | -46.3% | -38.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$235.81M totalProduct$117.10M · 49.7%
ROLVEDON$68.22M · 28.9%
INDOCINProducts$18.91M · 8.0%
Sympazan$11.35M · 4.8%
Product Other$10.67M · 4.5%
SPRIXNasal Spray$7.95M · 3.4%
Royalty$1.61M · 0.7%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Assertio Holdings against the 5 most active filers in the same SIC group.